Navigation Links
Compandia Announces Name Change and New Diagnostic Concept
Date:9/14/2010

Compandia Announces Name Change and New Diagnostic Concept -- NOTTINGHAM, England, September 15, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Compandia Announces Name Change and New Diagnostic Concept

 

NOTTINGHAM, England, September 15, 2010 /PRNewswire/ -- Compandia has announced a name change to CompanDX. The company is a biomarker discovery company providing services to the Pharma and Biotech sectors but increasingly, as a result of in-house R&D, is identifying biomarkers that may lead to new diagnostic services and products of its own. Andy Sutton CEO of CompanDX explained "we have grown the service side of the business over the last 9 months and are delivering biomarker discovery services to large pharma, small biotech and diagnostic companies. We and our investors have always recognised the significant upside potential in the research work we conduct with collaborators and in the laboratories of our founders, the new name reflects this activity as we start to build our IP portfolio around the signatures and biomarker panels we are developing."

CompanDX also announced the launch of its new "Time to an Event" breast cancer gene panel. CompanDX presents a plenary session today at the British Breast Cancer meeting in Nottingham describing the use of its Risk Distiller bioinformatics tools to deliver the first diagnostic that predicts time to a clinical event. CompanDX scientists have used three public datasets from different clinics to derive a 31 gene signature that predicts time to metastasis following initial surgery and biopsy. The gene signature was subsequently validated on a fourth dataset from yet another clinical centre. Across these patient cohorts the actual versus signature predicted time to metastases has a correlation of 0.86 (p< 0.0001). Furthermore CompanDX for the first time has predicted a "prospective Kaplan Meier curve" which accurately tracks the actual survival curve from the combined data. Here median time to event in the patient population was 3.5 years, this was predicted to be 3.7 years by the CompanDX gene signature with no significant differences between the actual and the CompanDX curves (p = 0.555). Andy Sutton commented "We are very excited about this study, firstly it is real world data from different labs, with no abstraction of outlying patient data. Furthermore it is a 'world first' of a totally new type of diagnostic paradigm with potential to significantly alter clinical management."

CompanDX has applied funding to validate this in the clinic and has secured collaboration with leading clinical centres in London, Nottingham, Cardiff and Holland and also industry support from a world leading diagnostics company in the development of the assay.


'/>"/>
SOURCE CompanDX
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Announces Partial Conversion of Isotechnika Debenture
2. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
3. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
4. Wintherix Announces Potent Small Molecule Wnt Activators for Bone Healing.
5. Southern Research Announces Completion of $20 Million Bond Transaction
6. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
7. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
8. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
9. RSB Spine, LLC, Announces Additional FDA Clearance for the InterPlate® L-Ti
10. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
11. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017 Summary ... understand Eli Lilly and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
(Date:3/27/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... toxicology and efficacy studies. The company is harnessing the ... protein, MAGE A, in an effort to find a ... After 4 weeks of treatment in transgenic mice, ... toxicity in a full toxicology report of various organs. ...
(Date:3/27/2017)... , March 27, 2017 ... 7,000 attendees and more than 600 exhibitors from ... discover opportunities and solutions that will advance the ... April 2017 at the Messe Stuttgart, ... preeminent medical technology platform showcasing the key trends ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
(Date:3/28/2017)... MO (PRWEB) , ... March 28, 2017 , ... ... of job satisfaction in their profession as their value increases in the healthcare ... that provides resources such as job boards, career fairs, and candidate leads to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... clear braces. People who want straight teeth without the extensive time commitment and ... Clearwater, FL, without acquiring a referral. A custom-designed series of virtually invisible aligners ...
(Date:3/27/2017)... and London UK (PRWEB) , ... March 27, ... ... speed, agility and ability to gain site attention and engagement over the household ... educational webinar will discuss how partnering with the right outsourcing ...
(Date:3/27/2017)... ... 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, ... and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle wearable devices, ... second annual venture competition ignites bold ideas by providing women access to the tools, ...
Breaking Medicine News(10 mins):